Ocular graft-versus-host disease

Current Opinion in Allergy and Clinical Immunology

Volumn 12, Issue 5, 2012, Pages 540-547

  Hessen, Michelle ^a   Akpek, Esen K ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

dry eye; graft versus host disease; ocular surface disease; treatment

Indexed keywords

ARTIFICIAL TEAR; BENZALKONIUM CHLORIDE; CD34 ANTIGEN; CELL ADHESION MOLECULE; CORTICOSTEROID; CYCLOSPORIN A; EPIDERMAL GROWTH FACTOR; FIBRONECTIN; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; METHOTREXATE; MYCOPHENOLIC ACID; NITRIC OXIDE; STEROID; TACROLIMUS; TRANILAST; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ANEMIA; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BLEPHARITIS; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMOSIS; CONJUNCTIVAL HYPEREMIA; CONTACT LENS; CORNEA EROSION; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; DRY EYE; ESOPHAGUS STENOSIS; EYE DISEASE; EYELID DISEASE; FASCIITIS; FIBROBLAST; FIBROSIS; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KERATOCONJUNCTIVITIS SICCA; KERATOPATHY; LACRIMAL GLAND; LICHEN (DISEASE); MAJOR HISTOCOMPATIBILITY COMPLEX; MEIBOMIAN GLAND; NATURAL KILLER CELL; NONHUMAN; PATHOPHYSIOLOGY; POIKILODERMA; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUVA; RETINA HEMORRHAGE; REVIEW; RISK FACTOR; SCLERITIS; SJOEGREN SYNDROME; T CELL DEPLETION; T LYMPHOCYTE; THROMBOCYTOPENIA; VAGINA DISEASE;

DRY EYE SYNDROMES; EYE DISEASES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84865988766     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e328357b4b9     Document Type: Review

References (66)

1. Appelbaum DR, Forman SJ, Negrin RS, Blume KG. Thomas' hematopoietic cell transplantation. 4th ed. Oxford: England:Wiley-Blackwell; 2009. pp. 705-1199.
2. Balaram M, Rashid S, Dana R. Chronic ocular surface disease after allogeneic bone marrow transplantation. Ocul Surf 2005; 3:203-211.
3. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 373:1550-1561.
4. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institute of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11:945-956.
5. Anderson NG, Regillo C. Ocular Manifestations of graft versus host disease. Curr Opin Ophthalmol 2004; 15:503-507.
6. Kim SK, Smith J, Dunn J. Chronic ocular graft versus host disease. In: Vogelsang GB, Pavletic SZ, editors. Chronic Graft versus Host Disease: Interdisciplinary Management. New York, NY: Cambridge University Press; 2009. pp. 199-206.
7. Kim SK. Update on ocular graft versus host disease. Curr Opin Ophthalmol 2006; 17:344-348.
8. Westeneng AC, Hettinga Y, Lokhorst H, et al. Ocular graft-versus-host disease after allogeneic stem cell transplantation. Cornea 2010; 7:758-763.
9. Ogawa Y, Kuwana M. Dry eye as a major complication associated with chronic graft-versus-host disease after hematopoietic stem cell transplantation. Cornea 2003; 22:S19-S27.
10. Tabbara KF, Al-Ghamdi, Al-Mohareb F, et al. Ocular findings after allogeneic hematopoietic stem cell transplantation. Ophthalmology 2009; 116:1624-1629.
11. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296:301-305.
12. Xun CQ, Thompson JS, Jennings CD, et al. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versushost disease in H-2-incompatible transplanted SCID mice. Blood 1994; 83:2360-2367.
13. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000; 95:2754-2759.
14. Hill GR, Crawford JM, Cooke KR, et al. Total body irradiation and acute graftversus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 90:3204-3213.
15. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol 2007; 7:340-352.
16. Dustin ML. Role of adhesion molecules in activation signaling in T lymphocytes. J Clin Immunol 2001; 21:258-263.
17. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 2007; 25:139-170.
18. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Eng J Med 1991; 324:667-674.
19. De Wit D, Van Mechelen M, Zanin C, et al. Preferential activation of the Th2 cells in chronic graft-versus-host reaction. J Immunol 1993; 150:361-366.
20. McCormick LL, Zhang Y, Tootell E, et al. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol 1999; 163:5593-5699.
21. Anderson BE, McNiff JM, Jain D, et al. Distinct roles for donor and host derived antigen-presenting cells and constimulatory molecules in murine chronic graft-versus-host disease: requirements depend of target organ. Blood 2005; 105:2227-2234.
22. Franklin RM, Kenyon KR, Tutschka PJ, et al. Ocular manifestations of graftversus-host disease. Ophthalmol 1983; 90:4-13.
23. Saito T, Shinagawa K, Takenaka K, et al. Ocular manifestations of acute graftversus-host disease after allogeneic peripheral blood stem cell transplantation. Int J Hematol 2002; 75:332-334.
24. Jack MK, Jack GM, Sale GE, et al. Ocular manifestations of graft-versus-host disease. Arch Ophthalmol 1983; 101:1080-1084.
25. Rojas B, Cuhna R, Zafrakis P, et al. Cell populations and adhesion molecules expression in conjunctiva before and after bone marrow transplantation. Exp Eye Res 2005; 81:313-325.
26. Riemens A, Boome L, Imhof S. Current insights into Ocular graft-versus-host disease. Curr Opin Ophthalmol 2010; 21:485-494.
27. Ogawa Y, Okamoto S, Wakui M, et al. Dry eye after haematopoietic stem cell transplantation. Br J Ophthalmol 1999; 83:1125-1130.
28. Kerty E, Vigander K, Flage T, Brinch L. Ocular findings in allogeneic stem cell transplantation without total body irradiation. Ophthalmology 1999; 106: 1334-1338.
29. Menucci R, Rossi Ferrini C, Bosi A, et al. Ophthalmological aspects in allogeneic bone marrow transplantation:Sjogren-like syndrome in graft-versus-host disease. Eur J Ophthalmol 1997; 7:13-18.
30. Tichelli A, Duell T, Weiss M, et al. Late-onset keratoconjunctivitis sicca syndrome after bone marrow transplantation: Incidence and risk factors. Bone Marrow Transplant 1996; 17:1105-1111.
31. Johnson DA, Jabs DA. The ocular manifestations of graft-versus-host disease. Int Ophthalmol Clin Spring 1997; 37:119-133.
32. Kim SK, Couriel D, Ghosh S, et al. Ocular graft vs. host disease experience from MD Anderson Cancer Center: newly described clinical spectrum and new approach to the management of Stage II and IV ocular GVHD. Biol Blood Marrow Transplant 2006; 12:S49.
33. Westeneng AC, Hettinga Y, Lokorst H, et al. Ocular graft-versus-host disease after transplantation. Cornea 2010; 29:758-763.
34. Sheidow TG, Sexton B, Hooper PL, et al. Vitritis as primarymanifestation od graft-versus-host disease: a case report with vitreous cytopathology. Can J Ophthalmol 2004; 39:667-671.
35. Moon SJ, Mieler WF. Retinal complications of bone marrow and solid organ transplantation. Curr Opin ophthalmol 2003; 14:442-443.
36. Kim RY, Anderlini P, Naderi AA, et al. Scleritis as the initial clinical manifestation of graft-versus-host diease after allogenic bone marrow transplantation. Am J Ophthalmol 2002; 133:843-845.
37. Fawzi AA, Cunningham ET Jr. Central serous chorioretinopathy after bone marrow transplantation. Am J Ophthalmol 2001; 131:804-805.
38. Kaiserman I, Or R. Laser photocoagulation for central serous retinopathy associated with graft-versus-host disease. Ocul Immunol Inflamm 2005; 13:249-256.
39. MacMillan ML, Weisdorf DJ, Davies SM, et al. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versushost disease. Biol Bone Marrow Transplant 2002; 8:40-46.
40. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host diease: a phase II study. Lancet 2008; 371:1579-1586.
41. Gatza E, Rogers CE, Clouthier SG, et al. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood 2008; 112:1515-1521.
42. Townley J, Dana R, Jacobs D. Keratoconjunctivitis sicca manifestations in ocular graft versus host disease: pathogenesis, presentation, prevention, and treatment. Semin Ophthalmol 2011; 26:251-260.
43. Bernauer W, Thiel MA, Kurrer M, et al. Corneal calicifications following intensified treatment with sodium hyaluronate artificial tears. Br J Ophthalmol 2006; 90:285-288.
44. Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol 2004; 137:337-342.
45. Robinson MR, Lee SS, Rubin BI, et al. Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease. Bone Marrow Transplant 2004; 33:1031-1035.
46. McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf 2002; 25:33-55.
47. Pflugfelder SC, Wilhelmus KR, Osato MS, et al. The auto-immune nature of aqueous tear deficiency. Ophthalmology 1986; 93:1513-1517.
48. Stern ME, Gao J, Siemasko KF, et al. The role of the lacrimal gland functional unit in the pathophysiology of dry eye. Exp Eye Res 2004; 78: 409-416.
49. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporine A ophthalmic emulsion in the treatment of moderate to severe dry eye disease: a dose-ranging, randomized trial. The Cyclospoine A Phase 2 Study Group. Ophthalmology 2000; 107:967-974.
50. Sall K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000; 107:631-639.
51. Laibovitz RA, Solch S, Andriano K, et al. Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca. Cornea 1993; 12:315-323.
52. Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol 2002; 120:330-337.
53. Dastjerdi MH, Hamrah P, Dana R. High frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen. Cornea 2009; 28:1091-1096.
54. Gupta A, Sadeghi PB, Akpek EK. Occult thyroid eye disease in patients presenting with dry eye symptoms. Am J Ophthalmol 2009; 147:919-923.
55. Malta JB, Soong HK, Shtein RM. Treatment of ocular graft-versus-host disease with topical cyclosporine 0.05% Cornea 2010; 29:1392-1396.
56. Balaram M, Schaumberg DA, Dana MR. Efficacy and tolerability outcomes after punctal occlusion with silicone plugs in dry eye syndrome. Am J Ophthalmol 2001; 131:129-136.
57. Chiang CC, Lin JM, Chen WL, Tsai YY. Allogeneic serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Cornea 2007; 26:861-863.
58. Fox RI, Chan R, Michelson JB, et al. Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis Rheum 1984; 27:459-461.
59. Van Setten GB, Viinikka L, Tervo T, et al. Epidermal growth factor is a constant component of normal human tear fluid. Graefes Arch C in Exp Ophthalmol 1989; 227:184-187.
60. Ogawa Y, Okamoto S, Mori T, et al. Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transplant 2003; 31:579-583.
61. Tsubota K, Goto E, Fujita H, et al. Treatment of dry eye by autologous serum application in Sjogren's syndrome. Br J Ophthalmol 1999; 83:390-395.
62. Jacobs D, Rosenthal P. Boston scleral lens prosthetic device for treatment of severe dry eye in chronic graft-versus-host disease. Cornea 2007; 26:1195-1199.
63. Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit 1995; 17:584-591.
64. Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from Streptomyces. I. Fermentation isolation, and physio-chemical and biological characteriztics. J antibiot (Tokyo) 1987; 40:1249-1255.
65. de Pailis A, Cirillo R, Ciccarelli A, et al. Antiinflammatory effect of FK-506 on human basophils. Tranplant Proc 1991; 23:2905-2906.
66. Ogawa Y, Dogru M, Uchino M, et al. Topical tranilast for treatment of early stage of mild dry eye associated with chronic GVHD. Bone Marrow Transplant 2010; 45:565-569.